Erik Stomrud
31 – 40 of 168
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
(
- Contribution to journal › Article
-
Mark
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
(
- Contribution to journal › Article